STOK
Price
$13.25
Change
+$0.08 (+0.61%)
Updated
Aug 7 closing price
Capitalization
723.41M
3 days until earnings call
SYRE
Price
$15.24
Change
-$0.72 (-4.51%)
Updated
Aug 7 closing price
Capitalization
920.51M
90 days until earnings call
Interact to see
Advertisement

STOK vs SYRE

Header iconSTOK vs SYRE Comparison
Open Charts STOK vs SYREBanner chart's image
Stoke Therapeutics
Price$13.25
Change+$0.08 (+0.61%)
Volume$418.36K
Capitalization723.41M
Spyre Therapeutics
Price$15.24
Change-$0.72 (-4.51%)
Volume$417.79K
Capitalization920.51M
STOK vs SYRE Comparison Chart in %
Loading...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
STOK vs. SYRE commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STOK is a Hold and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (STOK: $13.25 vs. SYRE: $15.24)
Brand notoriety: STOK and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: STOK: 63% vs. SYRE: 69%
Market capitalization -- STOK: $723.41M vs. SYRE: $920.51M
STOK [@Biotechnology] is valued at $723.41M. SYRE’s [@Biotechnology] market capitalization is $920.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STOK’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • STOK’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, STOK is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STOK’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • STOK’s TA Score: 4 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than STOK.

Price Growth

STOK (@Biotechnology) experienced а +3.11% price change this week, while SYRE (@Biotechnology) price change was -10.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

STOK is expected to report earnings on Aug 11, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($921M) has a higher market cap than STOK($723M). STOK has higher P/E ratio than SYRE: STOK (16.06) vs SYRE (1.72). STOK YTD gains are higher at: 20.127 vs. SYRE (-34.536). STOK has higher annual earnings (EBITDA): 40.3M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. STOK (357M). SYRE has less debt than STOK: SYRE (0) vs STOK (2.35M). STOK has higher revenues than SYRE: STOK (191M) vs SYRE (0).
STOKSYRESTOK / SYRE
Capitalization723M921M79%
EBITDA40.3M-214.36M-19%
Gain YTD20.127-34.536-58%
P/E Ratio16.061.72936%
Revenue191M0-
Total Cash357M565M63%
Total Debt2.35M0-
FUNDAMENTALS RATINGS
STOK vs SYRE: Fundamental Ratings
STOK
SYRE
OUTLOOK RATING
1..100
8066
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4299
PRICE GROWTH RATING
1..100
4259
P/E GROWTH RATING
1..100
2383
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (53) in the null industry is in the same range as SYRE (75) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to SYRE’s over the last 12 months.

STOK's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to SYRE’s over the last 12 months.

STOK's SMR Rating (42) in the null industry is somewhat better than the same rating for SYRE (99) in the Pharmaceuticals Major industry. This means that STOK’s stock grew somewhat faster than SYRE’s over the last 12 months.

STOK's Price Growth Rating (42) in the null industry is in the same range as SYRE (59) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to SYRE’s over the last 12 months.

STOK's P/E Growth Rating (23) in the null industry is somewhat better than the same rating for SYRE (83) in the Pharmaceuticals Major industry. This means that STOK’s stock grew somewhat faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STOKSYRE
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 17 days ago
85%
Declines
ODDS (%)
Bearish Trend 11 days ago
84%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PREPX26.93N/A
N/A
Principal Real Estate Securities R5
AIGIX22.08N/A
N/A
Alger International Opportunities I
RSGGX26.31N/A
N/A
Victory RS Global A
TIHAX13.76N/A
N/A
Transamerica International Stock A
LIOTX10.43N/A
N/A
Issachar I